Home » Stocks » GTH

Genetron Holdings Limited (GTH)

Stock Price: $19.95 USD -0.08 (-0.40%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $19.80 -0.15 (-0.75%) Apr 16, 4:33 PM
Market Cap 1.77B
Revenue (ttm) 64.91M
Net Income (ttm) -469.27M
Shares Out 88.87M
EPS (ttm) -7.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $19.95
Previous Close $20.03
Change ($) -0.08
Change (%) -0.40%
Day's Open 20.08
Day's Range 18.71 - 20.19
Day's Volume 182,238
52-Week Range 9.03 - 31.54

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in molecular profiling tests...

5 days ago - Business Wire

BEIJING, April 01, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offeri...

2 weeks ago - GlobeNewsWire

BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH) sponsored a Science/AAAS Webinar, “Early cancer screening today and tomorrow: Exploring liquid biops...

2 weeks ago - Business Wire

BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profil...

3 weeks ago - Business Wire

BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in molecular profiling tests...

3 weeks ago - Business Wire

BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profi...

1 month ago - Business Wire

BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology company in China that specializes in offering molecular profiling test...

1 month ago - Business Wire

BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profil...

1 month ago - Business Wire

BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH), a leading precision oncology company in China that specializes in offering molecular profiling tes...

2 months ago - Business Wire

BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH), a leading precision oncology company in China that specializes in offering molecular profiling tes...

2 months ago - Business Wire

BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profi...

3 months ago - Business Wire

NANJING, China--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH), a leading precision oncology company in China that specializes in offering molecular profil...

3 months ago - Business Wire

Genetron Health, a Beijing-North Caroline diagnostic company, announced a city-wide early screening test for liver cancer in Wuxi city using the company's blood-based HCCscreen. Sinopharm has filed for ...

Other stocks mentioned: SHTDY
4 months ago - Seeking Alpha

BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profi...

4 months ago - Business Wire

BEIJING--(BUSINESS WIRE)--The global COVID-19 pandemic has highlighted the critical importance of early detection and intervention in fighting other life-threatening diseases, such as cancer, according ...

4 months ago - Business Wire

BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profi...

4 months ago - Business Wire

BEIJING, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offerin...

5 months ago - GlobeNewsWire

Genetron Holdings went public in June 2020 and just reported its Q3 2020 results. The firm provides a range of cancer diagnostic and monitoring services in China.

5 months ago - Seeking Alpha

BEIJING, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering...

5 months ago - GlobeNewsWire

BEIJING, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offerin...

5 months ago - GlobeNewsWire

BEIJING, China, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in o...

5 months ago - GlobeNewsWire

Collaboration and equity investment to provide Genetron Health with significant know-how in immune profiling and accelerate MRD product development in hematologic cancer Collaboration and equity investm...

5 months ago - GlobeNewsWire

Designation represents Genetron Health’s first step to potentially expand the geographical reach of HCCscreen™ Designation represents Genetron Health’s first step to potentially expand the geographical ...

6 months ago - GlobeNewsWire

China has a considerably large gene pool, a decisive success factor in conducting prospective research in early-stage cancer studies. Local bureaucracy has the power to lead nationwide research.

6 months ago - Seeking Alpha

BEIJING and SUZHOU, China, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in off...

6 months ago - GlobeNewsWire

Genetron Health to present data at ESMO 2020 relating to precision oncology diagnostic development initiatives across lung, gastrointestinal and other cancer types, and to bioinformatics development

7 months ago - GlobeNewsWire

Collaboration to pioneer “one-stop” R&D solutions to empower the full cycle of new drug development in oncology Collaboration to pioneer “one-stop” R&D solutions to empower the full cycle of new drug de...

7 months ago - GlobeNewsWire

BEIJING, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offe...

7 months ago - GlobeNewsWire

BEIJING, Aug. 29, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offer...

7 months ago - GlobeNewsWire

China accounts for more than 26% of the world's cancer deaths.

8 months ago - Forbes

Genetron CEO on Covid-19 Diagnostic Kits, Pandemic, Oncology

YouTube video

Sizhen Wang, co-founder and chief executive officer at Genetron Health, discusses developing diagnostic kits for Covid-19 which received approval for export from China, how the pandemic has changed the ...

8 months ago - Bloomberg Markets and Finance

BEIJING, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH), a leading precision oncology company in China that specializes in offering mole...

8 months ago - GlobeNewsWire

BEIJING, July 29, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offeri...

8 months ago - GlobeNewsWire

BEIJING, July 27, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology company in China that specializes in offering molecu...

8 months ago - GlobeNewsWire

BEIJING, June 30, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company that covers full-cycle cancer care...

9 months ago - GlobeNewsWire

Genetron Holdings Ltd. gth shares rose 10% in their trading debut Friday, after the company's IPO priced above its price range.

9 months ago - Market Watch

Genetron Holdings Ltd. priced its initial public offering at $16 per American depositary share, selling 16 million ADS to raise $256 million.

9 months ago - Market Watch

About GTH

Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of liver cancer. It also provides in-vitro diagnostics products, including 8-gene Lung Cancer Assay, an IVD assay product based on semiconductor sequencing to... [Read more...]

Industry
Diagnostics & Research
IPO Date
Jun 19, 2020
Stock Exchange
NASDAQ
Ticker Symbol
GTH
Full Company Profile

Financial Performance

In 2020, GTH's revenue was 424.49 million, an increase of 31.25% compared to the previous year's 323.43 million. Losses were -3.07 billion, 354.0% more than in 2019.

Financial numbers in millions CNY.
Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for GTH stock is "Strong Buy." The 12-month stock price forecast is 25.52, which is an increase of 27.92% from the latest price.

Price Target
$25.52
(27.92% upside)
Analyst Consensus: Strong Buy